T K Nordt
Overview
Explore the profile of T K Nordt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
276
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Nordt T, Bode C
Z Kardiol
. 2000 May;
89(3):219-26.
PMID: 10798278
Reduced activity of the endogenous fibrinolytic system contributes to intramural deposition of microthrombi in atherogenesis and to intraluminal deposition of thrombi leading to acute complications of atherosclerosis such as acute...
12.
Nordt T, Peter K, Bode C, Sobel B
J Clin Endocrinol Metab
. 2000 Apr;
85(4):1563-8.
PMID: 10770198
Troglitazone, a novel oral insulin sensitizer, normalizes increased plasma activity of plasminogen activator inhibitor type 1 (PAI-1) in hyperinsulinemic patients such as women with polycystic ovary syndrome and patients with...
13.
Nordt T, Moser M, Kohler B, Kubler W, Bode C
Thromb Haemost
. 2000 Mar;
82 Suppl 1:121-3.
PMID: 10695501
In acute myocardial infarction rapid, complete, and sustained reperfusion of the infarct-related coronary artery is the most important therapeutic principle. Lanoteplase or n-PA, a third-generation plasminogen activator consisting of a...
14.
Peter K, Weirich U, Nordt T, Ruef J, Bode C
Thromb Haemost
. 2000 Mar;
82 Suppl 1:38-43.
PMID: 10695484
An increasing number of descriptive reports on soluble adhesion molecules and association with various diseases are published. Throughout these reports soluble adhesion molecules are identified as markers of inflammation. Since...
15.
Ruef J, Peter K, Nordt T, Runge M, Kubler W, Bode C
Thromb Haemost
. 2000 Mar;
82 Suppl 1:32-7.
PMID: 10695483
The initiating event of atherogenesis is thought to be an injury to the vessel wall resulting in endothelial dysfunction. This is followed by key features of atherosclerotic plaque formation such...
16.
Nordt T, Peter K, Ruef J, Kubler W, Bode C
Thromb Haemost
. 2000 Mar;
82 Suppl 1:14-8.
PMID: 10695479
Cardiovascular disease is responsible for approximately 50% of total mortality in Europe, the USA and Japan. Established risk factors including smoking, hypercholesterolemia, and hypertension explain about half of the incidence...
17.
Ruef J, Nordt T, Peter K, Runge M, Kubler W, Bode C
Thromb Haemost
. 1999 Aug;
82(1):109-14.
PMID: 10456463
Thrombolysis is well established in the treatment of acute myocardial infarction. However, clinical application of thrombolytic agents has limitations with respect to efficacy and specificity. To achieve highly effective and...
18.
Nordt T, Moser M, Kohler B, Ruef J, Peter K, Kubler W, et al.
Thromb Haemost
. 1998 Dec;
80(6):881-6.
PMID: 9869154
Rationale: Reocclusion after thrombolysis diminishes the benefits of early reperfusion after acute myocardial infarction (AMI). No clinical or laboratory variables have been identified as predictors for reocclusion yet. Methods And...
19.
Nordt T, Sawa H, Fujii S, Bode C, Sobel B
J Mol Cell Cardiol
. 1998 Sep;
30(8):1535-43.
PMID: 9737940
Diabetes mellitus is associated with an increased incidence and greater severity of primary atherosclerosis as well as restenosis after angioplasty for reasons not yet clear. We have shown previously that...
20.
Nordt T, Kornas K, Peter K, Fujii S, Sobel B, Kubler W, et al.
Circulation
. 1997 Feb;
95(3):677-83.
PMID: 9024157
Background: Insulin and its precursors found in increased plasma concentrations in non-insulin-dependent diabetes mellitus (NIDDM) augment synthesis of plasminogen activator inhibitor type 1 (PAI-1) in Hep G2 cells in vitro...